Homepage
Author:
InflaRx N.V.
Posted Date:
April 9, 2026
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
InflaRx N.V.
April 9, 2026
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
InflaRx N.V.
March 31, 2026
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
InflaRx N.V.
March 30, 2026
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
InflaRx N.V.
March 19, 2026
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
InflaRx N.V.
March 18, 2026
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
InflaRx N.V.
March 13, 2026
InflaRx to Report Full Year 2025 Results on March 19, 2026
InflaRx N.V.
March 12, 2026
InflaRx Announces Participation in February Investor Conferences
InflaRx N.V.
January 29, 2026
